Results 221 to 230 of about 146,762 (298)

First‐in‐class inhibitors of SbnA reduce siderophore production in Staphylococcus aureus

The FEBS Journal, EarlyView.
The production of the iron‐chelating compound staphyloferrin B by the most invasive S. aureus strains is crucial for colonization, virulence, and survival in the host. Staphyloferrin B biosynthesis is carried out by eight enzymes, the Sbn system, that offer an appealing source of potential targets for the development of antimicrobials.
Sarah Hijazi, Monica Cozzi, Somayeh Asgharpour, Omar De Bei, Serena Faggiano, Francesco Marchesani, Luca Ronda, Marialaura Marchetti, Eleonora Gianquinto, Mariacristina Failla, Gauthier Trèves, Loretta Lazzarato, Francesca Spyrakis, Barbara Campanini, Emanuela Frangipani, Stefano Bettati   +15 more
wiley   +1 more source

Mechanistic insights into proton-coupled substrate translocation of nucleoside proton symporters. [PDF]

J Biol Chem
Xiao Q, Chen X, Wang C, He Y, Deng D, Sun B.   +5 more
europepmc   +1 more source

FORMATION OF RIBONUCLEOSIDES FROM BASES BY NUCLEOSIDE PRODUCING MUTANTS OF BAGILLUS SUBTILIS

, 1965
Akio Yamanoi, Yoshiteru Hirose, Teruo SHIRO, Noboru Katsuya   +3 more
openalex   +2 more sources

Comparison of treatment‐emergent resistance‐associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor‐based single‐tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta‐analysis

HIV Medicine, EarlyView.
Abstract Objective This study evaluated rates of treatment‐emergent resistance‐associated mutations (TE‐RAMs) and discontinuation due to adverse events (DC‐AEs) across integrase strand transfer inhibitor (INSTI)‐based single‐tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV.
Ishfaq Rashid, Nathan R. Unger, Connor Willis, Teerapon Dhippayom, Moti Ramgopal, Elizabeth M. Sherman, Nicholas Yared, Rachel Safran, Edwin Swiatlo, Amy R. Weinberg, Soodi Navadeh, Howard Weston Schmutz, Nathorn Chaiyakunapruk   +12 more
wiley   +1 more source

Prevalence of drug resistance mutations in low-level viremia patients under antiretroviral therapy in Southwestern China: a cross-sectional study. [PDF]

J Antimicrob Chemother
Shu Y, Liu J, Yang C, Li J, Zhang M, Li Y, Deng X, Dong X.   +7 more
europepmc   +1 more source

The role of DNA in RNA synthesis, IX. Nucleoside triphosphate termini in RNA polymerase products.

, 1965
Umadas Maitra, H Hurwitz
openalex   +1 more source

Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment‐experienced people living with HIV: A feasibility survey

HIV Medicine, EarlyView.
Abstract Introduction As life expectancy among persons with HIV on antiretroviral therapy (ART) is increasing, comorbidities and polypharmacy increase. Drug–drug interactions (DDIs) are common among persons with HIV with a history of virological failure, since many are receiving boosted ART.
Marie Ballif, Manuela Correia da Silva Saúde, David Haerry, Marcel Stoeckle, Patrick Schmid, Dominique Braun, Alexandra Calmy, Gilles Wandeler, Bernard Surial   +8 more
wiley   +1 more source

HIV-1 subtype distribution and drug resistance profiles among PLWHA with detectable viremia in Henan Province, China, 2023. [PDF]

Sci Rep
Liu J, Fu C, Yang X, Zhang X, Wei S, Ma J, Zhao Q, Huo Y.   +7 more
europepmc   +1 more source

Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV

HIV Medicine, EarlyView.
Abstract Introduction Randomized controlled trial evidence suggests that long‐acting injectable (LA‐I) cabotegravir and rilpivirine (CAB+RPV) has similar virological failure (VF) rates to daily oral therapy, but clinical practice evidence is lacking. Integrase inhibitor (INI) resistance may limit future therapy.
Kyle Ring, Alexa Elias, Megan Devonald, Melanie Smuk, Chloe Orkin   +4 more
wiley   +1 more source

Pharmacokinetic simulations for remdesivir and its metabolites in healthy subjects and patients with renal impairment. [PDF]

Front Pharmacol
Zhang S, Jeong S, Jiang B, Ho H.
europepmc   +1 more source